Colistin, Meropenem-Vaborbactam, Imipenem-Relebactam, and Eravacycline Testing in Carbapenem-Resistant Gram-Negative Rods: A Comparative Evaluation of Broth Microdilution, Gradient Test, and VITEK 2

被引:0
|
作者
Forstner, Patrick [1 ]
Fuchs, Lisa [1 ]
Luxner, Josefa [1 ]
Grisold, Andrea [1 ]
Steinmetz, Ivo [1 ]
Dichtl, Karl [1 ]
机构
[1] Med Univ Graz, Diagnost & Res Inst Hyg Microbiol & Environm Med, A-8010 Graz, Austria
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 11期
关键词
VITEK; 2; AST-XN24; gradient test; <italic>Pseudomonas aeruginosa</italic>; <italic>Acinetobacter baumannii</italic> complex; Enterobacterales; carbapenem-resistant organism; colistin; eravacycline; meropenem-vaborbactam; imipenem-relebactam; IN-VITRO ACTIVITY; ACINETOBACTER-BAUMANNII; ENTEROBACTERIACEAE; SURVEILLANCE; PNEUMONIAE; ETEST;
D O I
10.3390/antibiotics13111062
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives. This study aimed to evaluate and compare the performance of different assays for antimicrobial susceptibility testing (AST) and minimum inhibitory concentration (MIC) determination for reserve antibiotics in carbapenem-resistant Enterobacterales (CREs), Pseudomonas aeruginosa (CRPAs), and Acinetobacter baumannii (CRABs). Methods. An analysis was conducted on 100 consecutive isolates: 50 CREs, 35 CRPAs, and 15 CRABs. Sensititre broth microdilution was used as a reference standard to evaluate the performance of VITEK 2 card AST-XN24 (bioM & eacute;rieux), the respective gradient tests (bioM & eacute;rieux), and UMIC colistin broth microdilution test strips (Bruker Daltonics). Errors, essential agreement (EA), and categorical agreement of MICs for colistin (COL), meropenem-vaborbactam (MVB), imipenem-relebactam (IRL), and eravacycline (ERV) were assessed. Results. The agreement between both of the COL broth microdilution (BMD) methods was perfect (100/100). The gradient test and VITEK 2 analysis yielded comparable EA rates (92/100 and 72/79, respectively), with the latter not registering any very major errors (VMEs). The MVB gradient test achieved EA in 66 of 85 isolates and VITEK 2 in 70/85. For IRL, EA was reached in 69 and 64 of 85 cases by gradient test and VITEK 2 analysis, respectively. The ERV gradient test yielded false results in nearly all (12/15) CRABs but achieved EA in 46 of 50 CREs. The VITEK system recorded EA for ERV in 60 of 65 isolates. Conclusions. We observed substantial variability in the measured MICs between BMD and the alternative methods. In only a few constellations, VITEK 2 or gradient tests could substitute the reference method. BMD is the method of choice for COL analysis, with VITEK 2 representing an alternative method for CRPA testing. Alternative methods for MVB did not provide reliable results, except for Enterobacterales, when tested with the gradient test. However, resistant results need to be confirmed by BMD. Only BMD can be used for IRL MIC determination. VITEK 2 was mostly accurate in measuring ERV MICs, while the corresponding gradient test yielded reliable results exclusively in CREs. It is essential that laboratories are aware of which testing method provides reliable results for each combination of microorganisms and reserve antibiotics.
引用
收藏
页数:10
相关论文
共 29 条
  • [1] Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens
    Biagi, M.
    Shajee, A.
    Vialichka, A.
    Jurkovic, M.
    Tan, X.
    Wenzler, E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (04)
  • [3] In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
    Bonnin, Remy A.
    Bernabeu, Sandrine
    Emeraud, Cecile
    Naas, Thierry
    Girlich, Delphine
    Jousset, Agnes B.
    Dortet, Laurent
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [4] Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa
    Sophonsri, Anthony
    Kalu, Michelle
    Wong-Beringer, Annie
    ANTIBIOTICS-BASEL, 2024, 13 (05):
  • [5] Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
    Sfeir, Maroun M.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (08) : 1484 - 1485
  • [6] Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution
    Hakvoort, Hanna
    Bovenkamp, Evelyn
    Greenwood-Quaintance, Kerryl E.
    Schmidt-Malan, Suzannah M.
    Mandrekar, Jay N.
    Schuetz, Audrey N.
    Patel, Robin
    JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (10)
  • [7] Comparative Evaluation of Colistin-Susceptibility Testing in Carbapenem-Resistant Klebsiella pneumoniae Using VITEK, Colistin Broth Disc Elution, and Colistin Broth Microdilution
    Antony, Tessa
    Senthilnathan, Yugadharshini
    Madhavakumar, Rukmani
    Amudhan, Premika
    Venkataraman, Shruthi
    Rally, Sanjana
    Pitani, Ravi S.
    Arumugam, Ilakkiya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [8] In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens
    Xu, Chunquan
    Chen, Tao
    Zhang, Siqin
    Zhou, Cui
    Liao, Wenli
    Fang, Renchi
    Chen, Lijiang
    Zhou, Tieli
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 103 (03)
  • [9] In-vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt
    Gadallah, Mona Abd El-Aziz
    El-sayed, Wasila Moursy
    Hussien, Mohammed Zakaria
    Elheniedy, Mohammed Ahmed
    Maxwell, Sara Youssef
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (03) : 205 - 218
  • [10] Evaluation of imipenem-relebactam susceptibility testing in carbapenem resistant Pseudomonas aeruginosa: comparison of sensititre microplates, disc diffusion, and MTS gradient strips with broth microdilution
    Biguenet, Adrien
    Devoos, Lea
    Rousselot, Julie
    Bour, Maxime
    Fournier, Damien
    Jeannot, Katy
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2025,